{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:30:21Z","timestamp":1781332221859,"version":"3.54.1"},"reference-count":156,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"crossref","award":["25-25-00373"],"award-info":[{"award-number":["25-25-00373"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple sclerosis (MS) is a chronic, heterogeneous, multifactorial, immune-mediated neurodegenerative disease of the central nervous system that affects the working-age population. Its development is influenced by both genetic and environmental factors. A pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, which are associated with neuronal damage caused by autoaggressive immune factors (T cells, B cells, and myeloid cells). Focal lesions are believed to be caused by the infiltration of immune cells into the central nervous system (CNS) parenchyma with concomitant tissue damage. Multiple sclerosis represents a significant social problem due to the high cost of available treatments, as well as the deterioration of employment prospects and job retention for both patients and their caregivers. Advances in MS diagnostic methods have enabled disease detection at early stages and correction of immune response impairments. Concurrently, treatments for MS patients are actively being studied, with the ongoing development of novel methods for targeted and cellular immunotherapy. This review primarily discusses approaches to cellular immunotherapy and methods of influencing the cellular arm of immunopathogenesis in multiple sclerosis.<\/jats:p>","DOI":"10.3390\/ijms27020585","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:09:36Z","timestamp":1767712176000},"page":"585","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cellular Immunotherapies for Multiple Sclerosis: Mechanistic Insights and Clinical Advances"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5617-0450","authenticated-orcid":false,"given":"Vasily","family":"Kurilin","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution \u201cResearch Institute of Fundamental and Clinical Immunology\u201d (RIFCI), Novosibirsk 630099, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6261-7557","authenticated-orcid":false,"given":"Marina","family":"Fisher","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution \u201cResearch Institute of Fundamental and Clinical Immunology\u201d (RIFCI), Novosibirsk 630099, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2180-3243","authenticated-orcid":false,"given":"Irina","family":"Obleukhova","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution \u201cResearch Institute of Fundamental and Clinical Immunology\u201d (RIFCI), Novosibirsk 630099, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7366-7768","authenticated-orcid":false,"given":"Sergey","family":"Sennikov","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution \u201cResearch Institute of Fundamental and Clinical Immunology\u201d (RIFCI), Novosibirsk 630099, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1089\/jicm.2022.0610","article-title":"Effect of acupuncture on sensorimotor function and mobility in patients with multiple sclerosis: A pilot study","volume":"29","author":"Karpatkin","year":"2023","journal-title":"J. Integr. Complement. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"111826","DOI":"10.1016\/j.intimp.2024.111826","article-title":"Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis","volume":"131","author":"Boleixa","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Claflin, S.B., Broadley, S., and Taylor, B.V. (2018). The effect of disease modifying therapies on disability progression in multiple sclerosis: A systematic overview of Meta-analyses. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.01150"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Xavier, A., Campagna, M.P., Maltby, V.E., Kilpatrick, T., Taylor, B.V., Butzkueven, H., Ponsonby, A.-L., Scott, R.J., Jokubaitis, V.G., and Lea, R.A. (2023). Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1162796"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomized, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"ASCEND investigators. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"D\u2019Souza, C., Prince, H.M., and Neeson, P.J. (2021). Understanding the role of T cells in the Antimyeloma effect of immunomodulatory drugs. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.632399"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00415-016-8183-3","article-title":"Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: A prospective web-based multicenter study in multiple sclerosis patients with a relapse","volume":"263","author":"Jongen","year":"2016","journal-title":"J. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Hafler","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103341","DOI":"10.1016\/j.msard.2021.103341","article-title":"Inducing chimeric antigen receptor (CAR) regulatory T cells In Vivo: A novel concept for a potential feasible cure of demyelinating diseases","volume":"57","author":"Sedaghat","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10072-011-0859-y","article-title":"Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China","volume":"33","author":"Chen","year":"2012","journal-title":"Neurol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/bmt.2009.141","article-title":"European Group for Blood and Marrow Transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe 2009","volume":"45","author":"Ljungman","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.exphem.2008.03.001","article-title":"High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis","volume":"36","author":"Shevchenko","year":"2008","journal-title":"Exp. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/sj.bmt.1700944","article-title":"Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: First results of a pilot study","volume":"20","author":"Fassas","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.57.1.62","article-title":"Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS","volume":"57","author":"Saccardi","year":"2001","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/1352458512438454","article-title":"A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A position paper","volume":"18","author":"Saccardi","year":"2012","journal-title":"Mult. Scler."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02806.x","article-title":"Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: Results from phase I\/II studies, prospective randomized trials and future directions","volume":"141","author":"Tyndall","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11910-014-0478-0","article-title":"Autologous bone marrow transplantation for the treatment of multiple sclerosis","volume":"14","author":"Radaelli","year":"2014","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/bmt.2014.277","article-title":"Autologous hematopoietic SCT normalizes miR-16,-155 and-142-3p expression in multiple sclerosis patients","volume":"50","author":"Arruda","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1042\/CS20140095","article-title":"Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis","volume":"128","author":"Malmegrim","year":"2015","journal-title":"Clin. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/brain\/awl370","article-title":"Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis","volume":"130","author":"Metz","year":"2007","journal-title":"Brain"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.3174\/ajnr.A0644","article-title":"A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis","volume":"28","author":"Rocca","year":"2007","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_24","first-page":"42","article-title":"Stromal stem cells: Marrow-derived osteogenic precursors","volume":"Volume 136","author":"Owen","year":"1988","journal-title":"Ciba Foundation Symposium 136\u2014Cell and Molecular Biology of Vertebrate Hard Tissues: Cell and Molecular Biology of Vertebrate Hard Tissues: Ciba Foundation Symposium 136"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(13)61810-3","article-title":"Cell therapy for multiple sclerosis: An evolving concept with implications for other neurodegenerative diseases","volume":"382","author":"Rice","year":"2013","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1471-4159.2009.06553.x","article-title":"Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival","volume":"114","author":"Kemp","year":"2010","journal-title":"J. Neurochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/STROKEAHA.110.593863","article-title":"Endogenous tissue plasminogen activator mediates bone marrow stromal cell-induced neurite remodelling after stroke in mice","volume":"42","author":"Shen","year":"2011","journal-title":"Stroke"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood.V99.10.3838","article-title":"Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli","volume":"99","author":"Magni","year":"2002","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9283","DOI":"10.3390\/ijms16059283","article-title":"Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis","volume":"16","author":"Xiao","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.mayocp.2019.01.001","article-title":"Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases","volume":"94","author":"Staff","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ferrara, G., Ivaldi, F., Mancardi, G., Kerlero de Rosbo, N., and Uccelli, A. (2021). Bone Marrow Transfer in Relapsing-Remitting EAE Ameliorates Disease at First Remission, with No Synergistic Effect upon Co-Transplantation with Mesenchymal Stem Cells. Vaccines, 9.","DOI":"10.3390\/vaccines9070736"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41392-022-01134-4","article-title":"Stem cell-based therapy for human diseases","volume":"7","author":"Hoang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1745-6215-12-62","article-title":"The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: An open-label pretest: Posttest study with blinded outcome assessments","volume":"12","author":"Connick","year":"2011","journal-title":"Trials"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1177\/13524585211062173","article-title":"Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES","volume":"28","author":"Karussis","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1474-4422(21)00301-X","article-title":"Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): A phase 2, randomized, double-blind crossover trial","volume":"20","author":"Uccelli","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/sctm.19-0430","article-title":"Mesenchymal stem cells as a multimodal treatment for nervous system diseases","volume":"9","author":"Badyra","year":"2020","journal-title":"Stem Cells Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wu, L., Lu, J., Lan, T., Zhang, D., Xu, H., Kang, Z., Peng, F., and Wang, J. (2024). Stem cell therapies: A new era in the treatment of multiple sclerosis. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1389697"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.stemcr.2014.04.005","article-title":"Human neural precursor cells promote neurologic recovery in a viral model of multiple sclerosis","volume":"2","author":"Chen","year":"2014","journal-title":"Stem Cell Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.msard.2014.08.002","article-title":"Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(11)70305-2","article-title":"Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study","volume":"11","author":"Connick","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","article-title":"Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study","volume":"227","author":"Yamout","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/1352458509359727","article-title":"MSCT Study Group. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the International MSCT Study Group","volume":"16","author":"Freedman","year":"2010","journal-title":"Mult Scler."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0165-5728(99)00106-X","article-title":"Multiple sclerosis is associated with high levels of circulating dendritic cells secreting proinflammatory cytokines","volume":"99","author":"Huang","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/1352458513505352","article-title":"Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors","volume":"20","author":"Thewissen","year":"2014","journal-title":"Mult Scler."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1365-2249.2000.01334.x","article-title":"Macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions","volume":"122","author":"Boven","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0165-5728(98)00002-2","article-title":"MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study","volume":"86","author":"McManus","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.4049\/jimmunol.0903662","article-title":"An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis","volume":"184","author":"Schwab","year":"2010","journal-title":"J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.it.2017.07.007","article-title":"Dendritic Cells as Inducers of Peripheral Tolerance","volume":"38","author":"Iberg","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Raker, V.K., Domogalla, M.P., and Steinbrink, K. (2015). Tolerogenic Dendritic Cells for Regulatory T-Cell Induction in Man. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00569"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/ni1265","article-title":"Inducing and expanding regulatory T-cell populations by foreign antigen","volume":"6","author":"Kretschmer","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Passeri, L., Marta, F., Bassi, V., and Gregori, S. (2021). Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168415"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"106275","DOI":"10.1016\/j.intimp.2020.106275","article-title":"Recent discoveries in dendritic cell tolerance-inducing pharmacological molecules","volume":"81","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/eji.201141835","article-title":"Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients","volume":"42","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Cauwels, A., and Tavernier, J. (2020). Tolerizing Strategies for the Treatment of Autoimmune Diseases: From ex vivo to In Vivo Strategies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00674"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.4049\/jimmunol.173.7.4331","article-title":"Antisense Oligonucleotides Down-Regulating Costimulation Confer Diabetes-Preventive Properties to Nonobese Diabetic Mouse Dendritic Cells","volume":"173","author":"Machen","year":"2004","journal-title":"J. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/jnr.24073","article-title":"The role of regulatory T cells in nervous system pathologies","volume":"96","author":"Duffy","year":"2018","journal-title":"J. Neurosci. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.it.2019.04.005","article-title":"Regulatory Immune Mechanisms Beyond Regulatory T Cells","volume":"40","author":"Christoffersson","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/imr.12165","article-title":"Homeostasis and function of regulatory T cells (Tregs) in vivo: Lessons from TCR-transgenic Tregs","volume":"259","author":"Attridge","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2006-01-0177","article-title":"Regulatory T-cell compartmentalization and trafficking","volume":"108","author":"Wei","year":"2006","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"104349","DOI":"10.1016\/j.neuint.2018.11.024","article-title":"Regenerating CNS myelin: Emerging roles of regulatory T cells and CCN proteins","volume":"130","author":"Dittmer","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"102175","DOI":"10.1016\/j.coph.2021.12.002","article-title":"Innate and adaptive immune mechanisms regulating central nervous system remyelination","volume":"63","author":"Creswell","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/bloodadvances.2019001248","article-title":"IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer","volume":"4","author":"Furlan","year":"2020","journal-title":"Blood Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/B978-0-12-380995-7.00004-5","article-title":"How tolerogenic dendritic cells induce regulatory T cells","volume":"108","author":"Maldonado","year":"2010","journal-title":"Adv. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gordon, J.R., Ma, Y., Churchman, L., Gordon, S.A., and Dawicki, W. (2014). Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol., 5.","DOI":"10.3389\/fimmu.2014.00007"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4239\/wjd.v12.i5.603","article-title":"Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes","volume":"12","year":"2021","journal-title":"World J. Diabetes"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e178949","DOI":"10.1172\/JCI178949","article-title":"Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis","volume":"134","author":"Fondelli","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"513295","DOI":"10.1155\/2015\/513295","article-title":"Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis","volume":"2015","author":"Xie","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Hong, W., Yang, B., He, Q., Wang, J., and Weng, Q. (2022). New Insights of CCR7 Signalling in Dendritic Cell Migration and Inflammatory Diseases. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.841687"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"De Laere, M., Derdelinckx, J., Hassi, M., Kerosalo, M., Oravam\u00e4ki, H., Van den Bergh, J., Berneman, Z., and Cools, N. (2018). Shuttling Tolerogenic Dendritic Cells across the Blood\u2013Brain Barrier In Vitro via the Introduction of De Novo C-C Chemokine Receptor 5 Expression Using Messenger RNA Electroporation. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01964"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2013.3022","article-title":"Transdermal application of myelin peptides in multiple sclerosis treatment","volume":"70","author":"Walczak","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gong, Y., Wang, Z., Liang, Z., Duan, H., Ouyang, L., Yu, Q., Xu, Z., Shen, G., Weng, X., and Wu, X. (2012). Soluble MOG35-55\/I-A(b) dimers ameliorate experimental autoimmune encephalomyelitis by reducing encephalitogenic T cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047435"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/80516","article-title":"Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand","volume":"6","author":"Bielekova","year":"2000","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e200190","DOI":"10.1212\/NXI.0000000000200190","article-title":"Ausimmune Investigator Group. HLA-DRB1*15:01 and the MERTK Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS","volume":"11","author":"Binder","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1189\/jlb.3A0714-334R","article-title":"MERTK as negative regulator of human T-cell activation","volume":"97","author":"Errasti","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e030309","DOI":"10.1136\/bmjopen-2019-030309","article-title":"RESTORE consortium. Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): A harmonized study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration","volume":"9","author":"Willekens","year":"2019","journal-title":"BMJ Open"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00109-008-0421-4","article-title":"Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE","volume":"87","author":"Huizinga","year":"2009","journal-title":"J. Mol. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"ltad012","DOI":"10.1093\/immadv\/ltad012","article-title":"Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: The route of administration","volume":"3","author":"Mansilla","year":"2023","journal-title":"Immunother. Adv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1365-2249.2002.01779.x","article-title":"Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis","volume":"127","author":"Pashenkov","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/cns.12342","article-title":"Beneficial effect of tolerogenic dendritic cells pulsed with MOG autoantigen in experimental autoimmune encephalomyelitis","volume":"21","author":"Mansilla","year":"2015","journal-title":"CNS Neurosci. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"106314","DOI":"10.1016\/j.intimp.2020.106314","article-title":"The role of chemokines and chemokine receptors in multiple sclerosis","volume":"83","author":"Cui","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Fl\u00f3rez-Grau, G., Zubizarreta, I., Cabez\u00f3n, R., Villoslada, P., and Benitez-Ribas, D. (2018). Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica from Preclinical to Clinical Trials. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01169"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e2300","DOI":"10.7717\/peerj.2300","article-title":"Minimum information about tolerogenic antigen-presenting cells (MITAP): A first step towards reproducibility and standardization of cellular therapies","volume":"4","author":"Lord","year":"2016","journal-title":"PeerJ"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"471719","DOI":"10.1155\/2015\/471719","article-title":"Clinical Use of Tolerogenic Dendritic Cells-Harmonization Approach in European Collaborative Effort","volume":"2015","author":"Hilkens","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Hosseinalizadeh, H., Rabiee, F., Eghbalifard, N., Rajabi, H., Klionsky, D.J., and Rezaee, A. (2023). Regulating the regulatory T cells as cell therapies in autoimmunity and cancer. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1244298"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Fisher, M.S., and Sennikov, S.V. (2025). T-regulatory cells for the treatment of autoimmune diseases. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1511671"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2153534","DOI":"10.1080\/21645515.2022.2153534","article-title":"Regulatory T-cell therapy for multiple sclerosis: Breaching (blood\u2013brain) barriers","volume":"18","author":"Verreycken","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Schl\u00f6der, J., Shahneh, F., Schneider, F.J., and Wieschendorf, B. (2022). Boosting regulatory T-cell function for the treatment of autoimmune diseases\u2014That is only half the battle!. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.973813"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nn.4528","article-title":"Regulatory T cells promote myelin regeneration in the central nervous system","volume":"20","author":"Dombrowski","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12079-017-0392-8","article-title":"Beyond immunomodulation: The regenerative role for regulatory T cells in central nervous system remyelination","volume":"11","author":"Miron","year":"2017","journal-title":"J. Cell Commun. Signal."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"287ra74","DOI":"10.1126\/scitranslmed.aaa8038","article-title":"Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis","volume":"7","author":"Cao","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"10476","DOI":"10.1038\/s41598-021-88448-5","article-title":"Multiple sclerosis patients have reduced resting and increased activated CD4+CD25+FOXP3+T regulatory cells","volume":"11","author":"Verma","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s42003-024-07381-1","article-title":"Metabolic reprogramming of naive regulatory T cells by IL-7 and IL-15 promotes their persistence and performance upon adoptive transfer","volume":"8","author":"Filoni","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Schmidt, A., Oberle, N., and Krammer, P.H. (2012). Molecular mechanisms of treg-mediated T-cell suppression. Front. Immunol., 3.","DOI":"10.3389\/fimmu.2012.00051"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13072-017-0129-1","article-title":"Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells","volume":"10","author":"Okada","year":"2017","journal-title":"Epigenetics Chromatin."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"a029025","DOI":"10.1101\/cshperspect.a029025","article-title":"Effector T Cells in Multiple Sclerosis","volume":"8","author":"Kaskow","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+CD25highCD127\u2212 regulatory T cells preserves \u03b2-cell function in type 1 diabetes in children","volume":"35","author":"Mysliwiec","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Hefazi, M., Bolivar-Wagers, S., and Blazar, B.R. (2021). Regulatory T-Cell Therapy of Graft-Versus-Host Disease: Advances and Challenges. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189676"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e200019","DOI":"10.1212\/NXI.0000000000200019","article-title":"Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons with Amyotrophic Lateral Sclerosis","volume":"9","author":"Thonhoff","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Duffy, S.S., Keating, B.A., and Moalem-Taylor, G. (2019). Adoptive Transfer of Regulatory T Cells as a Promising Immunotherapy for the Treatment of Multiple Sclerosis. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.01107"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41593-023-01432-2","article-title":"A genome-wide In Vivo CRISPR screen identifies essential regulators of T-cell migration to the CNS in a multiple sclerosis model","volume":"26","author":"Kendirli","year":"2023","journal-title":"Nat. Neurosci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: A novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J. Neuroinflamm."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Abraham, A.R., Maghsoudlou, P., Copland, D.A., Nicholson, L.B., and Dick, A.D. (2023). CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions. Front. Ophthalmol., 3.","DOI":"10.3389\/fopht.2023.1184937"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Muller, Y.D., Ferreira, L.M.R., Ronin, E., Ho, P., Nguyen, V., Faleo, G., Zhou, Y., Lee, K., Leung, K.K., and Skartsis, N. (2021). Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.686439"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"103859","DOI":"10.1016\/j.autrev.2025.103859","article-title":"Chimeric antigen receptor cell therapy: A revolutionary approach transforming cancer treatment to autoimmune disease therapy","volume":"24","author":"Wen","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Bednar, K.J., Lee, J.H., and Ort, T. (2022). Tregs in Autoimmunity: Insights Into Intrinsic Brake Mechanism Driving Pathogenesis and Immune Homeostasis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.932485"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"eaay6422","DOI":"10.1126\/scitranslmed.aay6422","article-title":"Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function","volume":"12","author":"Honaker","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Zhong, Y., and Stauss, H.J. (2024). Targeted Therapy of Multiple Sclerosis: A Case for Antigen-Specific Tregs. Cells, 13.","DOI":"10.3390\/cells13100797"},{"key":"ref_113","first-page":"e05822","article-title":"Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases","volume":"12","author":"Chen","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12185-016-2039-6","article-title":"Biology and clinical application of CAR T cells for B-cell malignancies","volume":"104","author":"Davila","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T-cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Labb\u00e9, R.P., Vessillier, S., and Rafiq, Q.A. (2021). Lentiviral Vectors for T-Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. Viruses, 13.","DOI":"10.3390\/v13081528"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/bs.mcb.2021.07.001","article-title":"Generation of CAR-T cells using lentiviral vectors","volume":"167","author":"Poorebrahim","year":"2022","journal-title":"Methods Cell Biol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Rauf, M.A., Rao, A., Sivasoorian, S.S., and Iyer, A.K. (2025). Nanotechnology-Based Delivery of CRISPR\/Cas9 for Cancer Treatment: A Comprehensive Review. Cells, 14.","DOI":"10.3390\/cells14151136"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: The evolution of CAR-T-cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41419-025-07454-x","article-title":"CAR-T therapy dilemma and innovative design strategies for next generation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"102596","DOI":"10.1016\/j.coi.2025.102596","article-title":"Chimeric antigen receptor T-cell therapy for autoimmune diseases","volume":"95","author":"Nie","year":"2025","journal-title":"Curr. Opin. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Vukovic, J., Abazovic, D., Vucetic, D., and Medenica, S. (2024). CAR-engineered T-cell therapy as an emerging strategy for treating autoimmune diseases. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1447147"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Gust, J., Ponce, R., Liles, W.C., Garden, G.A., and Turtle, C.J. (2020). Cytokines in CAR T-Cell-Associated Neurotoxicity. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.577027"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1002\/cam4.5818","article-title":"A second-generation CD38-CAR-T-cell for the treatment of multiple myeloma","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e001112","DOI":"10.1136\/lupus-2023-001112","article-title":"Mezagitamab in systemic lupus erythematosus: Clinical and mechanistic findings of CD38 inhibition in an autoimmune disease","volume":"11","author":"McDonnell","year":"2024","journal-title":"Lupus Sci. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Liu, X., Feng, Y., Song, Z., Liu, J., Luo, Z., Yu, G., and Wang, J. (2025). Novel and effective tandem CD38 and CD19 targeting CAR-T cells inhibit hematological tumor immune escape. Cell Immunol., 411\u2013412, 104950.","DOI":"10.1016\/j.cellimm.2025.104950"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B-cell malignancies: A phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Cao, L.Y., Zhao, Y., Chen, Y., Ma, P., Xie, J.C., Pan, X.M., Zhang, X., Chen, Y.C., Wang, Q., and Xie, L.L. (2025). CAR-T-cell therapy clinical trials: Global progress, challenges, and future directions from ClinicalTrials.gov insights. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1583116"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"24275","DOI":"10.1073\/pnas.1903854116","article-title":"Long-term In Vivo microscopy of CAR T-cell dynamics during eradication of CNS lymphoma in mice","volume":"116","author":"Mulazzani","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e124714","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein\u2013Barr virus-specific T-cell therapy for progressive multiple sclerosis","volume":"3","author":"Pender","year":"2018","journal-title":"JCI Insight"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1002\/cti2.1444","article-title":"Adoptive T-cell therapy targeting Epstein\u2013Barr virus as a treatment for multiple sclerosis","volume":"12","author":"Smith","year":"2023","journal-title":"Clin. Transl. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B-cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Yu, T., Jiao, J.H., and Wu, M.F. (2025). CAR-T cells in the treatment of multiple myeloma: An encouraging cell therapy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1499590"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: Phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T-cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1007\/s00415-024-12642-4","article-title":"Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: A systematic literature review","volume":"271","author":"Konitsioti","year":"2024","journal-title":"J. Neurol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of Anti-B-Cell Therapeutics in Autoimmune Neurological Diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Chatterjee, B., Deng, Y., Holler, A., Nunez, N., Azzi, T., Vanoaica, L.D., M\u00fcller, A., Zdimerova, H., Antsiferova, O., and Zbinden, A. (2019). CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein\u2013Barr virus infection in vivo. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007748"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2009.01.017","article-title":"Preventing and curing multiple sclerosis by controlling Epstein\u2013Barr virus infection","volume":"8","author":"Pender","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein\u2013Barr virus infection in the multiple sclerosis brain","volume":"204","author":"Serafini","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Ioannides, Z.A., Csurhes, P.A., Douglas, N.L., Mackenroth, G., Swayne, A., Thompson, K.M., Hopkins, T.J., Green, K.A., Blum, S., and Hooper, K.D. (2021). Sustained Clinical Improvement in a Subset of Patients with Progressive Multiple Sclerosis Treated with Epstein\u2013Barr Virus-Specific T-Cell Therapy. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.652811"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Behrens, M., Comabella, M., and L\u00fcnemann, J.D. (2024). EBV-specific T-cell immunity: Relevance for multiple sclerosis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1509927"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e00980-19","DOI":"10.1128\/JVI.00980-19","article-title":"Epstein\u2013Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism","volume":"93","author":"Serafini","year":"2019","journal-title":"J. Virol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Li, J., Zhang, Y., Fu, T., Xing, G., Cai, H., Li, K., Xu, Y., and Tong, Y. (2024). Clinical advances and challenges associated with TCR-T-cell therapy for cancer treatment. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1487782"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"107433","DOI":"10.1016\/j.phrs.2024.107433","article-title":"Targeting the autoreactive CD8+ T-cell receptor in type 1 diabetes: Insights from scRNA-seq for immunotherapy","volume":"209","author":"Lai","year":"2024","journal-title":"Pharmacol Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1006\/cimm.1994.1043","article-title":"T-cell receptor peptide therapy for autoimmune encephalomyelitis: Stronger immunization is necessary for effective vaccination","volume":"153","author":"Matsumoto","year":"1994","journal-title":"Cell Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Metaxakis, A., Petratou, D., and Tavernarakis, N. (2020). Molecular Interventions towards Multiple Sclerosis Treatment. Brain Sci., 10.","DOI":"10.3390\/brainsci10050299"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nm1096-1109","article-title":"Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial","volume":"2","author":"Vandenbark","year":"1996","journal-title":"Nat. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0165-5728(97)00029-5","article-title":"The results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide","volume":"76","author":"Gold","year":"1997","journal-title":"J. Neuroimmunol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e19763","DOI":"10.1016\/j.heliyon.2023.e19763","article-title":"Engineering chimeric autoantibody receptor T cells for targeted B-cell depletion in multiple sclerosis model: An In Vitro study","volume":"9","author":"Sahlolbei","year":"2023","journal-title":"Heliyon"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"12531","DOI":"10.1523\/JNEUROSCI.3599-07.2007","article-title":"A promising therapeutic approach for multiple sclerosis: Recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS","volume":"27","author":"Sinha","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2010.09.013","article-title":"RTL therapy for multiple sclerosis: A Phase I clinical study","volume":"231","author":"Offner","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Wens, I., Janssens, I., Derdelinckx, J., Meena, M., Willekens, B., and Cools, N. (2021). Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147536"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","article-title":"TCR-T-cell therapy: Current development approaches, preclinical evaluation, and perspectives on regulatory challenges","volume":"22","author":"Golikova","year":"2024","journal-title":"J. Transl. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/585\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:23:26Z","timestamp":1767849806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":156,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27020585"],"URL":"https:\/\/doi.org\/10.3390\/ijms27020585","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}